These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7390422)

  • 21. Psychopharmacoepidemiology of mental retardation: 1966 to 1995.
    Singh NN; Ellis CR; Wechsler H
    J Child Adolesc Psychopharmacol; 1997; 7(4):255-66. PubMed ID: 9542696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between nurse characteristics and perceptions of psychotropic medications in residential facilities for the retarded.
    Aman MG; Singh NN; Fitzpatrick J
    J Autism Dev Disord; 1987 Dec; 17(4):511-23. PubMed ID: 3680153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychotropic drug use in older developmentally disabled with behavioral difficulties.
    Harper DC; Wadsworth JS; Michael AL
    Res Dev Disabil; 1989; 10(1):53-60. PubMed ID: 2928579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving knowledge of psychotropic prescribing in people with Intellectual Disability in primary care.
    Shankar R; Wilcock M
    PLoS One; 2018; 13(9):e0204178. PubMed ID: 30216381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.
    Deb S; Unwin G; Deb T
    J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of psychotropic drugs in mentally handicapped adults].
    Meins W
    Psychiatr Prax; 1988 Nov; 15(6):218-22. PubMed ID: 3237896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ventricular enlargement in adults with profound mental retardation who demonstrate violent/destructive behaviors.
    May PB; DeMarco K; London EB; Thompson R; Mento TL; Buscemi L; Cody R
    J Neuropsychiatry Clin Neurosci; 2001; 13(1):96-100. PubMed ID: 11207335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Determinants of psychotropic medication in adults with mild or moderate intellectual disabilities].
    Schützwohl M; Voss E; Stiawa M; Salize HJ; Puschner B; Koch A
    Nervenarzt; 2017 Nov; 88(11):1273-1280. PubMed ID: 27638741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of psychotropic drug, response cost, and psychotropic drug plus response cost procedures for controlling institutionalized mentally retarded persons.
    Breuning SE; O'Neill MJ; Ferguson DG
    Appl Res Ment Retard; 1980; 1(3-4):253-68. PubMed ID: 7337461
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiepileptic drugs with mood stabilizing properties and their relation with psychotropic drug use in institutionalized epilepsy patients with intellectual disability.
    Leunissen CL; de la Parra NM; Tan IY; Rentmeester TW; Vader CI; Veendrick-Meekes MJ; Aldenkamp AP
    Res Dev Disabil; 2011; 32(6):2660-8. PubMed ID: 21752594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study.
    Bowring DL; Totsika V; Hastings RP; Toogood S; McMahon M
    J Intellect Disabil Res; 2017 Jun; 61(6):604-617. PubMed ID: 28090687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication use among Australian adults with intellectual disability in primary healthcare settings: a cross-sectional study.
    Doan TN; Lennox NG; Taylor-Gomez M; Ware RS
    J Intellect Dev Disabil; 2013 Jun; 38(2):177-81. PubMed ID: 23550741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of prolactin elevation by psychotropic drugs in people with intellectual disabilities].
    González-Pablos E; Martín-Lorenzo C; Valles-de la Calle JM; Paulino-Matos P
    Semergen; 2019; 45(8):e51-e52. PubMed ID: 31345685
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs.
    Scheifes A; Walraven S; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
    Res Dev Disabil; 2016; 49-50():13-21. PubMed ID: 26647003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychotropic and Anticonvulsant Medication: Individuals With Intellectual and Developmental Disabilities Who Transitioned to the Community From an Institution.
    Kelly S; Su Y
    Intellect Dev Disabil; 2015 Aug; 53(4):289-300. PubMed ID: 26214558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychotropic drug use in institutionalized people with mental retardation.
    Bond WS; Mandos LA; Kurtz MB
    DICP; 1989 Nov; 23(11):924-5. PubMed ID: 2596139
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability.
    Scheifes A; de Jong D; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER
    Res Dev Disabil; 2013 Oct; 34(10):3159-67. PubMed ID: 23886758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders.
    Edelsohn GA; Schuster JM; Castelnovo K; Terhorst L; Parthasarathy M
    Psychiatr Serv; 2014 Feb; 65(2):201-7. PubMed ID: 24233105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of problem behaviour during medication evaluations.
    Zarcone J; Napolitano D; Valdovinos M
    J Intellect Disabil Res; 2008 Dec; 52(12):1015-28. PubMed ID: 18717764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimising psychotropic medication prescribing to reduce adverse drug events.
    Strydom A; Melville C
    J Intellect Disabil Res; 2019 May; 63(5):369-371. PubMed ID: 30993818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.